News & Updates

Show Multimedia Only

ThuFLEP noninferior to HoLEP in terms of functional outcomes in BPO

25 Mar 2026 by

Thulium fiber laser enucleation of the prostate (ThuFLEP) was noninferior to Holmium laser enucleation of the prostate (HoLEP) in terms of functional outcomes through 24 months in patients with benign prostatic obstruction (BPO), according to a trial presented at EAU26.

ThuFLEP noninferior to HoLEP in terms of functional outcomes in BPO

25 Mar 2026

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

24 Mar 2026

The 2025 guidelines set by the American Urological Association (AUA) improve stratification of patients with microscopic hematuria (MH) into risk groups for urothelial cancer, but not renal cortical neoplasms of any kind, according to a study.

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

24 Mar 2026

Enzalutamide improves outcomes in prostate cancer with hrBCR

24 Mar 2026 by

Treatment with enzalutamide monotherapy demonstrates numerically higher overall survival (OS) in prostate cancer patients with high-risk biochemical recurrence (hrBCR) when compared with leuprolide alone, but the difference is not statistically significant, as shown by the results of the EMBARK study.

Enzalutamide improves outcomes in prostate cancer with hrBCR

24 Mar 2026

TXA POISEd for use in urologic surgery

24 Mar 2026 by

The POISE-3 trial supports the use of tranexamic acid (TXA) in patients undergoing urologic surgery at increased risk of bleeding.

TXA POISEd for use in urologic surgery

24 Mar 2026

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

Solid organ transplant (SOT) recipients with a history of cancer are at increased risk of post-transplant cancer, especially the same type of cancer, according to a study.

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

Original New Drug Application Approvals by US FDA (1-15 March 2026)

19 Mar 2026

New drug applications approved by US FDA as of 1-15 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 March 2026)

19 Mar 2026

Bladder-sparing regimen for MIBC shows promising antitumour activity

18 Mar 2026 by

In the treatment of patients with muscle-invasive bladder cancer (MIBC), a perioperative regimen of the antibody–drug conjugate sacituzumab govitecan plus pembrolizumab yields a promising clinical complete response rate without eliciting grade ≥4 adverse events (AEs), allowing bladder preservation without further therapy in some patients, according to the phase II SURE-02 trial.

Bladder-sparing regimen for MIBC shows promising antitumour activity

18 Mar 2026

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

17 Mar 2026 by

In patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy, neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab elicits improvements in event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rate relative to neoadjuvant gemcitabine plus cisplatin, according to the phase III KEYNOTE-B15 study.

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

17 Mar 2026

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

15 Mar 2026 by

The addition of hormone therapy, either short- or long-term, to postoperative radiotherapy (PORT) offers no survival advantage over PORT alone in prostate cancer, especially for men with very low pre-PORT prostate specific antigen (PSA) levels, according to the POSEIDON study.

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

15 Mar 2026

Enzalutamide plus radium-223 boosts OS in mCRPC

13 Mar 2026 by

Adding enzalutamide to radium-223 significantly improves overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with enzalutamide alone, according to the phase III EORTC 1333/PEACE-3 trial presented at ASCO GU 2026.

Enzalutamide plus radium-223 boosts OS in mCRPC

13 Mar 2026

News & Updates

Showing Urology articles

Showing

Specialty:

ThuFLEP noninferior to HoLEP in terms of functional outcomes in BPO

ThuFLEP noninferior to HoLEP in terms of functional outcomes in BPO

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

Enzalutamide improves outcomes in prostate cancer with hrBCR

Enzalutamide improves outcomes in prostate cancer with hrBCR

TXA POISEd for use in urologic surgery

TXA POISEd for use in urologic surgery

Malignant disease may re-emerge following SOT among cancer survivors

Malignant disease may re-emerge following SOT among cancer survivors

Original New Drug Application Approvals by US FDA (1-15 March 2026)

Original New Drug Application Approvals by US FDA (1-15 March 2026)

Bladder-sparing regimen for MIBC shows promising antitumour activity

Bladder-sparing regimen for MIBC shows promising antitumour activity

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

Enzalutamide plus radium-223 boosts OS in mCRPC

Enzalutamide plus radium-223 boosts OS in mCRPC